Iovance Biotherapeutics (IOVA) has had the highest return this year by a mid-cap US stock, returning 423.7%.
| ASSET | YEAR | % RETURN |
|---|---|---|
Iovance Biotherapeutics (IOVA) | 2026 | 423.74% |
MaxLinear (MXL) | 2026 | 399.1% |
Erasca (ERAS) | 2026 | 316.71% |
Penguin Solutions (PENG) | 2026 | 298.16% |
Pulse Biosciences (PLSE) | 2026 | 279.25% |
Aehr Test Systems (AEHR) | 2026 | 271.93% |
Abcellera Biologics (ABCL) | 2026 | 269.44% |
AXT (AXTI) | 2026 | 260.35% |
Veradermics (MANE) | 2026 | 260% |
Kodiak Sciences (KOD) | 2026 | 255.64% |
Okeanis Eco Tankers (ECO) | 2026 | 250.31% |
CareDx (CDNA) | 2026 | 235.03% |
International Seaways (INSW) | 2026 | 195.46% |
Hyperliquid Strategies Inc Common Stock (PURR) | 2026 | 194.62% |
Calumet Specialty Products Partners (CLMT) | 2026 | 189.18% |
Ichor (ICHR) | 2026 | 183.38% |
Applied Opt (AAOI) | 2026 | 177.01% |
Tango Therapeutics (TNGX) | 2026 | 173.11% |
Cohu (COHU) | 2026 | 172.39% |
Iridium Communications (IRDM) | 2026 | 172.04% |
Ringcentral (RNG) | 2026 | 171.09% |
Sellas Life Sciences (SLS) | 2026 | 168.09% |
Oruka Therapeutics (ORKA) | 2026 | 165.09% |
Delek US Energy (DK) | 2026 | 165.01% |
Enliven Therapeutics (ELVN) | 2026 | 163.48% |
Mid-cap stocks are treated as having a market cap between $2B and $10B.